skip to Main Content

Expert Point of View: Allyson J. Ocean, MD

Newsfeed image, light gray text on dark gray background
Allyson J. Ocean, MD, a pancreatic cancer specialist at New York-Presbyterian Hospital/Weill Cornell Medical Center and Associate Professor of Medicine at the Weill Medical College of Cornell University, commented on these study findings. “While I applaud the authors for the data presented, the abstract reports on outcomes before the era of combination chemotherapy such as FOLFIRINOX [leucovorin, fluorouracil, irinotecan, oxaliplatin] and gemcitabine plus nanoparticle albumin-bound paclitaxel [Abraxane],” she noted.

“With the development and more widespread use of combination chemotherapy and new drugs, outcomes are improving. We are making strides against this disease, but these breakthroughs and trials need to reach patients faster.” Read more . . .

Update on Overall Survival for Newly Diagnosed Patients With Metastatic Pancreatic Cancer

Back To Top